Newsletter Signup | Community
Checkpoint inhibitor Tecentriq improves outcomes of TNBC
Dr. Bhuvaneswari Ramaswamy of the OSU Arthur G. James Cancer Hospital answers frequently asked questions about TNBC
Novel Precision Medicine Promising in Triple-Negative Breast Cancer.
Erbitux May Increase Response Rates in Metastatic Triple-Negative Breast Cancer.
Triple Negative Breast Cancer Foundation
Checkpoint PD-1 inhibitors and Sacituzumab Govitecan (IMMU-132) promising treatment for triple negative breast cancer
Iniparib Promising in Metastatic Triple-negative Breast Cancer
Obesity Linked with Triple-Negative Breast Cancer
Triple Negative Breast Cancer Linked with Higher Rate of Distant Metastases.
Interesting data published this week show HDC appears to benefit TNBC: